Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23540530.
- Also identified by DOI 10.1021/nn4006544 and PMC identifier 3773536.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Here we present a biomimetic strategy toward nanoparticle design for controlled immune response through encapsulation of conserved internal influenza proteins on the interior of virus-like particles (VLPs) to direct CD8+ cytotoxic T cell protection. Programmed encapsulation and sequestration of the conserved nucleoprotein (NP) from influenza on the interior of a VLP, derived from the bacteriophage P22, results in a vaccine that provides multistrain protection against 100 times lethal doses of influenza in an NP specific CD8+ T cell-dependent manner. VLP assembly and encapsulation of the immunogenic NP cargo protein is the result of a genetically programmed self-assembly making this strategy amendable to the quick production of vaccines to rapidly emerging pathogens. Addition of adjuvants or targeting molecules were not required for eliciting the protective response.
Medical subject headings
- Histocompatibility Antigens Class II
- Nanoparticles
- Orthomyxoviridae Infections
- Vaccines, Virus-Like Particle